TransMedics: Revolutionizing The Organ Transplant Market While Trading At A Discount

TransMedics Group is a strong buy, leveraging its technological and logistical moat in organ transport, with OCS and NOP programs driving sector outperformance. TMDX trades at a 39x Non-GAAP PE and 5.2x NTM EV/Sales, appearing undervalued relative to its 20%-25% growth guidance and MedTech peers. Key growth catalysts include the OCS Kidney launch (late 2026/early 2027) and European expansion, particularly in Italy, positioning TMDX for significant volume upside.